Medical/Pharmaceuticals

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

SHANGHAI and HONG KONG, March 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...

2021-03-01 08:00 3198

Sirtex Medical receives positive recommendation from National Institute for Health and Care Excellence (NICE) for selective internal radiation therapy (SIRT) using SIR-Spheres®

NICE recommends SIR-Spheres® Y-90 microspheres as an option for treating unresectable advanced hepatocellular carcinoma (HCC) in adults WOBURN, Mass., Feb. 26, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, received positive...

2021-02-26 23:37 2982

LISCure Biosciences Successfully Raises $21 million in Series B Funding

SEOUL, South Korea, Feb. 26, 2021 /PRNewswire/ -- On February 25th, 2021, LISCure Biosciences Inc., a biotech company that focuses on developing bacteria-mediated immunotherapy, announced that it has successfully completed $21 million of a Series B funding round. Participants include institutional...

2021-02-26 22:00 3694

Alterity to present at the 7th International Congress of Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format fromFebruary 26-...

2021-02-26 20:45 6799

Debiopharm And Genome & Company Join Forces To Create New Highly Specific Therapies For Cancer Patients

Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates LAUSANNE, Switzerland and SEONGNAM-SI GYEONGGI-DO, South Korea, Feb. 26, 2021 /PRNewswire/ -- Genome & Company (CEO:Jisoo Pae, Hanso...

2021-02-26 19:14 4153

Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization

HANGZHOU, China, Feb. 26, 2021 /PRNewswire/ -- China National Medical Products Administration (NMPA) announced onFebruary 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the "Ad5-nCoV", trade name: Convidecia™). CanSino Biologics Inc. an...

2021-02-26 16:36 5583

Vela Diagnostics adds two SARS-CoV-2 assays for virus genotyping, and variant identification to its COVID-19 testing solutions

SINGAPORE, Feb. 26, 2021 /PRNewswire/ -- Vela Diagnostics announced that it has added ViroKey™ SQ FLEX SARS-CoV-2 Genotyping Assay and ViroKey™ SARS-CoV-2 ID RT-PCR Test to its portfolio offering. The ViroKey™ SQ FLEX SARS-CoV-2 Genotyping Assay (RUO) harnesses next-generation sequencing (NGS) t...

2021-02-26 16:00 2345

Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 26, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HBM4003, the next generati...

2021-02-26 10:16 7621

ARANZ Medical's Silhouette® system becomes a national platform for wound telehealth assessments

CHRISTCHURCH, New Zealand, Feb. 25, 2021 /PRNewswire/ -- The US Department of Veteran's Affairs (VA) is establishingARANZ Medical's Silhouette solution as a VA national platform, enabling more VA Medical Centers to utilize Silhouette in their wound telehealth programs.

2021-02-26 09:39 2071

Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform

BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen's antibody discove...

2021-02-25 23:45 1978

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in the phase 3 piv...

2021-02-25 21:00 5217

New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines

DARMSTADT, Germany, Feb. 25, 2021 /PRNewswire/ -- Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD® (cladribine tablets) in patients with relapsing multiple sclerosi...

2021-02-25 21:00 3263

Polyplastics Expands DURACON (R) POM PM Series with New High-flow Grade for Medical and Healthcare Industry

TOKYO, Feb. 25, 2021 /PRNewswire/ -- The Polyplastics Group is expanding its DURACON (R) polyoxymethylene (POM) PM series portfolio with the development of a new high-flow grade for drug contact and delivery applications for the medical and healthcare market. The new grade, DURACON PM27S01N, offe...

2021-02-25 15:00 4419

Elekta appoints Johan Adebäck as Chief Financial Officer

STOCKHOLM, Feb. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that Johan Adebäck has been appointed as permanent Chief Financial Officer with immediate effect. He has held the position of Acting CFO sinceJune 2, 2020. Prior to the Acting CFO position, Johan Adebäck had been Group Tr...

2021-02-25 14:52 5785

Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH

SHANGHAI, Feb. 24, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of nonalcoholic steatohepatitis (NASH), today announces the Investigational New Drug Application (IND) approval ...

2021-02-25 08:30 3736

WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories

SHANGHAI, Feb. 25, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the company has been named a winner of the 2021 CMO Leadership Awards for a fourth year in a row. The company is proud to ...

2021-02-25 08:00 2996

Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients

SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/ -- Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research ...

2021-02-25 07:00 2815

Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021

HONG KONG, Feb. 25, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...

2021-02-25 05:16 10595

Game-Changing Wrinkle Reduction Device Receives Key Regulatory Clearance in Canada

Sofwave is crucial to your aesthetic practice. Learn Why! YOQNEAM, Israel, Feb. 25, 2021 /PRNewswire/ -- Sofwave Medical, the emerging leader of energy-based non-invasive, skin treatment aesthetic medical devices, announced today that it received clearance from Health Canada for its next-generat...

2021-02-25 01:00 2352

Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI

Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence HONG KONG, Feb. 25, 2021 /PRNewswire/ -- Insilico Medicine has demonstrated a breakthrough in Artifici...

2021-02-25 00:48 3817
1 ... 632633634635636637638 ... 646

Week's Top Stories